MRI引导自适应放疗治疗高级别胶质瘤(UNITED):单中心、单臂、非劣效性2期试验
该单臂2期试验纳入98例病理确诊的胶质母细胞瘤患者,采用5毫米CTV的小边距、MRI引导自适应放疗,主要终点 Marginal failure 风险为4%(95%CI 0-8),非劣效于10%的历史对照。常见3-4级不良事件为淋巴细胞减少(11%)和血小板减少(4%),无治疗相关死亡。
要点
- MRI引导自适应放疗可实现胶质母细胞瘤边距缩减,边缘失败风险低(4%)。
- 3-4级不良事件以淋巴细胞减少和血小板减少为主,无治疗相关死亡。
- 需随机试验对比标准大边距放疗,以明确毒性和生活质量改善。
核心结论
- MRI引导自适应放疗使胶质母细胞瘤边距缩减,边缘失败风险为4%(95%CI 0-8),非劣效于10%的历史对照。
研究设计与样本
- 单中心、单臂、非劣效性2期试验,纳入98例病理确诊的胶质母细胞瘤患者,接受MRI引导自适应放疗。
主要发现
- 边缘失败风险为4%(95%CI 0-8)。
- 最常见3-4级不良事件为淋巴细胞减少(8/72,11%)和血小板减少(4/98,4%)。
- 严重不良事件发生于1例(1%)患者(发热性中性粒细胞减少),无治疗相关死亡。
关键数值与推荐
- CTV边距为5毫米,可个体化包括T2-FLAIR高信号区域。
- 放疗方案为长程60 Gy/30次/6周或短程40 Gy/15次/3周,同步每日放化疗。
- 主要终点非劣效界值为10%,对照历史数据。
临床怎么用
- 对于胶质母细胞瘤,MRI引导自适应放疗可安全地缩减边距,边缘失败率低。
局限性
- 单臂设计,非劣效比较基于历史对照。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Radiotherapy volumes for patients with glioblastoma have remained unchanged for decades and result in large volumes of irradiated brain. We aimed to show the safety of a small-margin, MRI-guided adaptive radiotherapy approach for glioblastoma. METHODS: This single-arm, phase 2 trial was done at Sunnybrook Health Sciences Centre, Toronto, ON, Canada, and included patients with pathologically confirmed glioblastoma and planned for concurrent daily chemoradiotherapy up to 60 Gy in 30 daily fractions over 6 weeks (long course) or 40 Gy in 15 daily fractions over 3 weeks (short course). Eligible patients were adults (≥18 years) with an expected life expectancy greater than 12 weeks and an Eastern Cooperative Oncology performance status less than or equal to 2. A 5 mm clinical target volume (CTV) was applied, with the allowance of associated T2-weighted fluid-attenuated inversion recovery hyperintense regions in a personalised way at the discretion of the treating physician. All patients were treated with 1·5 T MRI-guided linear accelerator (MR-Linac) incorporating weekly gadolinium-enhanced online adaptive fractions. The primary outcome was the risk of marginal failure powered for non-inferiority with a margin of 10% compared with a historical control. All patients were included in the primary and safety analyses. This study is registered with ClinicalTrials.gov, NCT04726397. FINDINGS: Between April 28, 2021, and May 12, 2023, 109 patients were assessed for eligibility and 98 were enrolled and received treatment on the UNITED protocol with 59 [60%] patients receiving long-course radiotherapy and 39 [40%] receiving short-course radiotherapy. Median follow-up was 14·2 months (IQR 8·9-19·7). 53 (54%) of 98 patients were male and 45 (46%) were female. The observed risk of marginal failure was 4% (95% CI 0-8). The most common grade 3-4 adverse events were lymphopenia (eight [11%] of 72 patients without baseline lymphopenia) and thrombocytopenia (four [4%] of 98 patients). Serious adverse events occurred in one (1%) patient due to febrile neutropenia and there were no treatment-related deaths. INTERPRETATION: MRI-guided adaptation for glioblastoma enables margin de-escalation and resulted in a low rate of marginal failure. A randomised trial comparing this technique to a standard large-margin radiotherapy approach will establish whether toxicity and quality-of-life improvements can be realised. FUNDING: None.
引用
- Detsky JS, Chan AW, Moore-Palhares D, et al. MRI-guided adaptive radiotherapy for high grade glioma (UNITED): a single-centre, single-arm, non-inferiority, phase 2 trial. Lancet Oncol. 2026. PMID: 42134380. doi:10.1016/S1470-2045(26)00088-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。